This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-22. Anything still debated is marked as such rather than presented as settled.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
=== Thickeners and Emulsifying agents === Topical cream formulations consist of the oily phase and water phase. As the two phases are immiscible, in the absence of thickeners and emulsifying agents, molecules in the topical cream formulation will form droplets. Rapid aggregation of droplets within each phase will eventually lead to phase separation. Physical stability is determined by the mitigation ability to these physical instability phenomena. Thickeners increase cream viscosity and thus reduce dispersed droplets' mobility. They hinder the separation of phases, thereby increases the physical stability of the cream. For example, the inclusion of methylcellulose and paraffin reduces dispersed droplets' mobility in an oil-in-water emulsion and water-in-oil emulsion respectively. Emulsifying agents can reduce the interfacial tension between the two phases, thus retards phase separation. Ionic surfactants are used in oil-in-water emulsions, whereas nonionic surfactants are used in both oil-in-water and water-in-oil formulations.
{\displaystyle {\begin{aligned}m_{\text{u}}&={\frac {m_{\text{e}}}{A_{\text{r}}({\text{e}})}}={\frac {2R_{\infty }h}{A_{\text{r}}({\text{e}})c\alpha ^{2}}}={\frac {M_{\text{u}}}{N_{\text{A}}}},\\[1ex]N_{\text{A}}&={\frac {M_{\text{u}}A_{\text{r}}({\text{e}})}{m_{\text{e}}}}={\frac {M_{\text{u}}A_{\text{r}}({\text{e}})c\alpha ^{2}}{2R_{\infty }h}},\end{aligned}}}
A major focus of pharmacometrics is to understand variability in drug response. Variability may be predictable (e.g., due to differences in body weight or kidney function) or apparently unpredictable (reflecting the current knowledge gap).
=== Cardioprotective activity === Didymin has been shown to protect against doxorubicin-induced cardiotoxicity in mouse models and cardiomyocyte cell cultures, reducing oxidative stress, mitochondrial dysfunction, and apoptosis via activation of the PI3K/Akt/Nrf2 signalling pathway. In endothelial cell studies, didymin prevented hyperglycaemia-induced dysfunction and death in human umbilical vein endothelial cells (HUVECs) by reducing ROS generation, lipid peroxidation, and inflammatory cytokine release, and by inhibiting NF-κB activation.
=== CNO-II === In a minor branch of the above reaction, occurring in the Sun's core 0.04% of the time, the final reaction involving 157N shown above does not produce carbon-12 and an alpha particle, but instead produces oxygen-16 and a photon and continues
Sources: en.wikipedia.org
=== No development reported === 4-Chlorokynurenine (4-CL-KYN; 7-CL-KYNA; AV-101) – ionotropic glutamate NMDA receptor antagonist and 3-hydroxyanthranilate oxidase inhibitor [146] α-Synuclein picobody (a-syn-pico) – positron-emission tomography (PET) enhancer – diagnosis [147] A-86929 – dopamine D1 receptor agonist [148] AB-4166 – microbiome modulator [149] ACI-12589 – positron-emission tomography (PET) enhancer – diagnosis [150] Affitope-PD03 (PD03; PD03A) – α-synuclein inhibitor and immunostimulant [151] ANPD-002 (ANPD002) – dopaminergic cell replacement [152] AP-472 – metabotropic glutamate mGlu4 receptor positive allosteric modulator [153] Aplindore (DAB-452; palindore; SLS-006; WAY-DAB 452) – dopamine D2 receptor agonist [154] Armesocarb (MLR-1019) – atypical dopamine reuptake inhibitor (DRI) [155] Atuzaginstat (COR-388) – peptide hydrolase inhibitor [156] ATV:aSyn (ATV:α-synuclein; ATV:αSyn) – α-synuclein inhibitor [157] Autologous adipose derived mesenchymal stem cells - Hope Biosciences – cell replacement [158] AZ-001 – undefined mechanism of action [159] Beperminogene perplasmid (AMG-0001; Collategene; hepatocyte growth factor gene therapy) – gene transference and hepatocyte growth factor (HGF) expression stimulant [160] BTRX-246040 (LY-2940094) – nociceptin receptor (NOP) antagonist [161] Cannabidiol/tetrahydrocannabinol (CBD/THC; CanChew; MedChew; THC/CBD) – cannabinoid CB1 and CB2 receptor agonist and other actions [162] Carbidopa/levodopa (WD-1603) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [163] Carbidopa/levodopa oral solution (EXN-32) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [164] Ciforadenant (CPI-444, V-81444) – adenosine A2A receptor antagonist CM-4612 (CM-ADHD; CM-AT; CM-PK) – enzyme replacement and modulator [165] Crisdesalazine (AAD-2004) – microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor [166] CTx-GBA1 – gene transference [167] Cu(II)ATSM (copper(II)-ATSM; Cu-ATSM) – neuron modulator [168] Debamestrocel (autologous bone marrow derived mesenchymal stem cell therapy; NurOwn) – dopaminergic cell replacement [169] DNL-201 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [170] Dopamine intranasal – non-selective dopamine receptor agonist [171] DX-0308 (DX-308) – retinoic acid metabolism modulator [172] Emrusolmin (anle-138b; TEV-56286) – α-synuclein inhibitor and protein aggregation inhibitor [173] ESB-1609 – sphingosine-1-phosphate (S1P) receptor agonist [174] ESB-5070 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [175] F-14413 – α2-adrenergic receptor inverse agonist [176] FB-101 (1ST-102) – Bcr-Abl tyrosine kinase inhibitor [177] Fibroblast growth factor 1 (FGF-1) – fibroblast growth factor stimulant and angiogenesis-inducing agent [178] GO-101 – gene transference [179] GT-02329 – β-glucocerebrosidase (GCase) activator and/or chaperone [180] ISC-hpNSC (human parthenogenetic neural stem cells) – dopaminergic cell replacement [181] Itanapraced (CHF-5074; CSP-1103) – γ-secretase modulator and non-steroidal anti-inflammatory drug (NSAID) derivative lacking cyclooxygenase (COX) inhibition [182] Levodopa deuterated (deuterium-containing levodopa; SD-1077) – dopamine precursor and indirect non-selective dopamine receptor agonist [183] Liatermin (BVF-014; GDNF; glial-derived neutrotrophic factor; r-metHuGDNF) – neuron stimulant [184] Lu-AE-04621 (Lu-AE04621) – dopamine receptor agonist (prodrug of Lu-AA40326) [185] Masupirdine (SUVN-502; SUVN502) – serotonin 5-HT6 receptor antagonist [186] Mesocarb (MLR-1017) – atypical dopamine reuptake inhibitor (DRI) [187] MTK-458 – protein-serine-threonine kinase stimulant [188] NPT-200-11 (NPT200-11; UCB-1332) – α-synuclein inhibitor [189] NPT-520-34 (NPT520-34) – 1-phosphatidylinositol 3 kinase modulator and other actions [190] ODM-104 – catechol O-methyltransferase (COMT) inhibitor [191] OP-101 (dendrimer N-acetylcysteine) – various actions [192] OP-501 – catechol O-methyltransferase (COMT) inhibitor [193] Ordopidine (ACR-325) – low-affinity dopamine D2 receptor antagonist and dopaminergic stabilizer [194] PD-04 (a-Syn-PD-04; Affitope PD-04; PD04) – peptide vaccine against α-synuclein [195] Rasagiline – monoamine oxidase B (MAO-B) inhibitor [196] Rasagiline transdermal patch (TPU-002RA) – monoamine oxidase B (MAO-B) inhibitor [197] Research programme: adenosine A2A/A1 selective antagonists - Domain Therapeutics/CleveXel Pharma (CVXL-0069; DT-1133; DT0926; FP-0692; FP-1133) – adenosine A1 receptor antagonists and adenosine A2A receptor antagonists [198] Research programme: catalytic antioxidants - Aeolus Pharmaceuticals (AEOL-10113; AEOL-11207) – antioxidants [199] Research programme: central nervous system therapeutics - Delpor – undefined mechanism of action [200] Research programme: cGAS/STING antagonists - IFM Due – nucleotidyltransferase inhibitors [201] Research programme: COMT inhibitors - Avalo Therapeutics (AVTX-406; CERC-425; CERC-406) – catechol O-methyltransferase (COMT) inhibitors [202] Research programme: dopamine D1 receptor agonists - Takeda – dopamine D1 receptor agonists [203] Research programme: exosome therapeutics - ArunA Biomedical – undefined mechanism of action [204] Research programme: GPCR modulators - Nxera Pharma – various actions [205] Research programme: KEAP1 inhibitors - Keapstone Therapeutics – Kelch-like ECH-associated protein 1 (KEAP1) inhibitors [206] Research programme: long-acting neuropsychiatric therapeutics - Teva (NP-201; NP-202; risperidone/ropinirole implants) – various actions [207] Research programme: LRRK2 inhibitor - GlaxoSmithKline – leucine-rich repeat kinase 2 (LRRK2) inhibitors [208] Research programme: LRRK2 inhibitors - Novartis – leucine-rich repeat kinase 2 (LRRK2) inhibitors [209] Research programme: neurodegenerative disorder gene therapies - Denali Therapeutics (AAV-LF2; CNS-directed AAV-based gene therapies) – gene transference [210] Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience (AD-0802; AD-1502; AD-2203; AE-1501; BAN-2203; BAN-2502; BAN2401 back-up) – various actions [211] Research programme: neurodegenerative disorder therapeutics - Celgene Corporation/Evotec (BMSxxx) – cell replacements [212] Research programme: neurodegenerative disease therapeutics - ProteoTech (DP-68; DP-74; PD-61-W3; PeptiClere; PTI-19; PTI-51; PTI-51-CH3; Synuclere; TauPro) – various actions [213] Research programme: neurological disorders therapeutics - Gloriana therapeutics (ECB-PD; ECT-PD; Meteorin; Ns-G34; NsG-0301; NsG-33) – glial cell line-derived neurotrophic factor modulators [214] Research programme: Parkinson's disease therapeutics - Alectos Therapeutics – glucocerebrosidase 2 (GBA2) protein inhibitor [215] Research programme: Parkinson's disease therapies - Zymes (co-Q10; coenzyme Q10; ubidecarenone) – antioxidants [216] Research programme: Parkinson's disease therapy - AbbVie – dopamine D2 and D3 receptor agonists [217] Research programme: positive allosteric modulators - Proximagen – various actions [218] Research programme: protective autoimmunity enhancer - Proneuron Biotechnologies (PN-277) – immunomodulators [219] Research programme: protein phosphatase 2A modulators - Signum Biosciences (SIG-1012; SIG-1106) – protein phosphatase 2A (PP2A) modulator [220] Research programme: small molecule therapeutics - Amathus Therapeutics – mitochondrial protein stimulants [221] Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma (ADA-308; ADA-409; Backup; MDA-308; MDA-409) – androgen receptor antagonists [222] Research programme: transmembrane protein 175 agonists - AbbVie/Caraway Therapeutics – TMEM175 stimulants [223] Rotigotine controlled release (SER-214) – non-selective dopamine receptor agonist and other actions [224] S-32504 – dopamine D2 and D3 receptor agonist [225] SAGE-324 (BIIB-124) – GABAA receptor positive allosteric modulator and neurosteroid [226] Saracatinib (AZD-0530) – Src-family kinase inhibitor [227] Selegiline transdermal (Emsam) – monoamine oxidase B (MAO-B) inhibitor and other actions [228] Seridopidine (ACR343; ACR-343) – dopamine receptor modulator and so-called "dopaminergic stabilizer" [229] SLS-004 (LV-dCas9-DNMT3A) – gene therapy and α-synuclein expression inhibitor [230] Sonlicromanol (KH-176) – prostaglandin-E synthase inhibitor and reactive oxygen species modulator [231] SPN-803 (SPN803) – undefined mechanism of action [232] STEL-101 (AMA-101; STL-101) – undefined mechanism of action [233] UB-312 – immunostimulant [234] YKP-10461 (SKL-PD; YKP10461) – monoamine oxidase B (MAO-B) inhibitor [235] YTX-7739 – stearoyl-CoA desaturase inhibitor [236] Xenon (NBTX-001) – ionotropic glutamate NMDA receptor antagonist [237]
Wood has been a key material in construction since ancient times, so its preservation by coating has received much attention. Efforts to improve the performance of wood coatings continue. Coatings are used to alter tribological properties and wear characteristics. These include anti-friction, wear and scuffing resistance coatings for rolling-element bearings Architectural coatings or paints are used to paint the exteriors and interiors of buildings, often called or external masonry coatings. Clear varnishes and lacquers are generally excluded. Such products are usually designated for specific purposes such as roof coatings, wall paints, or deck finishes. Coatings are eco-friendly building material that increases the efficiency of energy used and reduces impact on human well-being and the environment. The coatings are typically applied with brushes, rollers or sprayers. Wall coatings come in a variety of types, some of which can be applied by amateurs and DIYers without specialized training or equipment. For example, simple paint or primers can often be applied using brushes or rollers, and many people successfully complete such projects themselves. Most masonry surfaces can be treated an exterior wall coating, such as render, pebbledash, stone, stucco or brick.
=== Critical response === The first season received critical acclaim. The review aggregator Rotten Tomatoes reported an 100% approval rating based on 74 critics’ reviews, with an average rating of 8.3/10. The website's critics consensus states, "A prickling debut that pulls few punches, Hacks deftly balances its sharp critiques of the comedy world with more intimate moments, all the while giving the incomparable Jean Smart a role worthy of her talents – and an excellent partner in Hannah Einbinder." Metacritic calculated a weighted average score of 82 out of 100 based on 24 critics.
Acting as a pro-apoptotic protein in many contexts, the normal levels of this protein mean that, in most cases, the initiated cell-death signaling pathways have an influence on the mitochondrial apoptosis pathway. This protein can have a premature prolonged apoptotic response with the risk of having not enough galectin-7 to re-epithelialize, delaying wound repair and skin closure through skin cell migration. This can be seen in aged skin which is considered to be a potential reason why wound repair is delayed in older individuals who would have less of this protein in them. With varying roles depending on the cellular conditions and factors, the protein is researched under induced ectopic expression in cancerous conditions. The discovered association between apoptosis and an over expression of galectin-7 has been found in apoptotic keratinocytes. The possible issue of the process of re-epithelialization being compromised or delayed would result in painful and serious wound disorders that would be difficult to treat as it has already affected the human tissue. The dangers of failure of re-epithelialization causes concern for uncontrolled inflammation, especially in the intestinal tract, and other immune responses that are more general. The cause for this isn't so much the inability for cell proliferation but instead the potential for the epithelium to migrate across the bed of the wound decreasing.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.